Schlein Johanna, Kaider Alexandra, Gabriel Harald, Wiedemann Dominik, Hornykewycz Stephan, Simon Paul, Base Eva, Michel-Behnke Ina, Laufer Günther, Zimpfer Daniel
Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Ann Thorac Surg. 2023 Mar;115(3):656-662. doi: 10.1016/j.athoracsur.2022.05.061. Epub 2022 Jun 30.
Valve repair is the procedure of choice for congenital aortic valve disease. With increasing experience, the surgical armamentarium broadened from simple commissurotomy to more complex techniques. We report our 30-year experience with pediatric aortic valve repair.
A retrospective chart review of all patients aged less than 18 years who underwent aortic valve repair from May 1985 to April 2020 was conducted. Mortality was cross-checked with the national health insurance database (96% complete mortality follow-up in April 2020). Primary study endpoints were survival and incidence of reoperations.
From May 1985 until April 2020, 126 patients underwent aortic valve repair at a median age of 1.8 years (interquartile range, 0.2-10). Early mortality was 5.6% (7 of 126). All early deaths occurred in neonates with critical aortic stenosis undergoing commissurotomy. No early deaths were observed after 2002. Kaplan-Meier estimated survival was 90.8% (95% CI, 84.0-94.8) at 10 years, 86.9% (95% CI, 78.7-92.2) at 20 years, and 83.5% (95% CI, 71.7-90.6) at 30 years. The cumulative incidence of aortic valve replacement was 37% (95% CI, 27.7-46.3) at 10 years, 62.2% (95% CI, 50.1-72.1) at 20 years, and 67.4% (51.2-79.2) at 30 years. Nine patients had undergone re-repair of the aortic valve. The majority of valve replacements were Ross procedures.
Our results support a repair-first strategy for patients with congenital heart disease and underline that aortic valve reconstruction can be a successful long-term solution. Longevity did not differ between aortic valve commissurotomy and complex aortic valve reconstruction.
瓣膜修复是先天性主动脉瓣疾病的首选治疗方法。随着经验的增加,手术器械从简单的交界切开术扩展到更复杂的技术。我们报告了我们30年来小儿主动脉瓣修复的经验。
对1985年5月至2020年4月期间接受主动脉瓣修复的所有18岁以下患者进行回顾性病历审查。死亡率与国家健康保险数据库进行交叉核对(2020年4月死亡率随访完成率为96%)。主要研究终点是生存率和再次手术的发生率。
从1985年5月到2020年4月,126例患者接受了主动脉瓣修复,中位年龄为1.8岁(四分位间距,0.2 - 10岁)。早期死亡率为5.6%(126例中的7例)。所有早期死亡均发生在接受交界切开术的重症主动脉瓣狭窄新生儿中。2002年后未观察到早期死亡。Kaplan-Meier估计10年生存率为90.8%(95%置信区间,84.0 - 94.8),20年生存率为86.9%(95%置信区间,78.7 - 92.2),30年生存率为83.5%(95%置信区间,71.7 - 90.6)。10年时主动脉瓣置换的累积发生率为37%(95%置信区间,27.7 - 46.3),20年时为62.2%(95%置信区间,50.1 - 72.1),30年时为67.4%(51.2 - 79.2)。9例患者接受了主动脉瓣再次修复。大多数瓣膜置换是罗斯手术。
我们的结果支持对先天性心脏病患者采用先修复的策略,并强调主动脉瓣重建可以是一种成功的长期解决方案。主动脉瓣交界切开术和复杂主动脉瓣重建的长期生存率无差异。